Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs

Author:

Zhou Haiyan1,Toshiyoshi, Maeda2,Zhao Wenli3,Zhao Ye4ORCID,Zhao, Yan5

Affiliation:

1. Department of Medicine, Yueyang Vocational Technical College, Yueyang, China

2. International Education College, Shandong University of Traditional Chinese Medicine, Jinan, China

3. Liver Center, Saga University Hospital, Saga University, Saga, Japan

4. Department of Public Health, International College, Krirk University, Bangkok, Thailand

5. Department of Public Health, International College, Krirk University, Bangkok, Thailand.

Abstract

Background: The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising rapidly in the world. Our aim is to investigate the efficacy and safety of statins in the treatment of NAFLD. Methods: This study was conducted by searching The National Library of Medicine, Cochrane Library, China National Knowledge Infrastructure, Web of Science, and Wanfang Data Knowledge Service Platform databases. Literature data are expressed as mean difference (MD) and 95% confidence intervals (CIs) or relative risk and 95% CI. For I 2 > 50% trials, random effect model is used for statistical analysis, otherwise fixed effect model is used. Results: Fourteen studies are selected for this meta-analysis, which includes totally 534 patients in the treatment group and 527 patients in the control group. As a result, 5 studies show that the total effective rate of the treatment group is 17% higher than that of the control group (Z = 2.11, relative risk = 1.17, 95% CI: [1.01–1.35]). Twelve studies show that alanine aminotransferase levels of the experimental group are lower than that of the control group (Z = 2.63, P = .009, MD = −5.53, 95% CI: [−9.64 to −1.41]). Eleven studies show that aspartate transaminase levels of the experimental group are lower than that of the control group (Z = 2.01, P = .04, MD = −3.43, 95% CI: [−6.77 to −0.08]). Six studies show that alkaline phosphatase levels of the experimental group are lower than that of the control group (Z = 0.79, P = .43, MD = −3.46, 95% CI: [−12.08 to 5.16]). Eight studies show that gamma-glutamyl transpeptidase levels of the experimental group are lower than that of the control group (Z = 2.04, P = .04, MD = −4.05, 95% CI: [−7.96 to −0.15]). Thirteen studies show that triglyceride levels of the experimental group are lower than that of the control group (Z = 4.15, P < .0001, MD = −0.94, 95% CI: [−1.39 to −0.50]). Eleven studies show that the total cholesterol levels of the experimental group are lower than that of the control group (Z = 5.42, P < .00001, MD = −1.51, 95% CI: [−2.05 to −0.96]). Seven studies show that low-density lipoprotein-cholesterol levels of the experimental group are lower than that of the control group (Z = 5.00, P < .00001, MD = −0.85, 95% CI: [−1.18 to −0.52]). Conclusion: Statins can significantly reduce liver biochemical indicators in patients with NAFLD.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3